Adnexus Buy Aimed At Enhancing Bristol’s Transformation To Biopharma Business
Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.
Acquisition valued at $430 million comes seven months after firms signed oncology development deal, which "exceeded our expectations," Bristol told "The Pink Sheet" DAILY.